Momenta and Sandoz appeal
Momenta and Sandoz have filed for an interlocutory, mid-trial appeal against a US court decision that let Amphastar proceed with its antitrust case alleging the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin”.
You may also be interested in...
Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.
Are nanoparticle data necessarily relevant to every ingredient assessment undertaken by Cosmetic Ingredient Review’s independent expert panel? Let us be the judge of that, the panel said on 27 September at its 162nd meeting.
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.